BGLC — Bionexus Gene Lab Cashflow Statement
0.000.00%
Last trade - 00:00- $5.32m
- $4.03m
- $7.42m
Annual cashflow statement for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 0.752 | -0.356 | -2.63 | -1.6 | -2.98 |
| Depreciation | |||||
| Non-Cash Items | 0.029 | -0.017 | 1.13 | -0.855 | 1.02 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.862 | 0.833 | 0.118 | 0.115 | 0.012 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 0.009 | 0.552 | -1.3 | -2.23 | -1.84 |
| Capital Expenditures | -0.003 | -0.054 | -0.149 | -0.227 | -0.037 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.487 | -0.396 | -0.233 | 0.645 | 0.982 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.491 | -0.451 | -0.383 | 0.418 | 0.945 |
| Financing Cash Flow Items | -0.002 | -0.008 | 0.004 | 0.004 | 0.299 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.028 | 0.108 | 5.75 | 0.145 | 0.299 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.664 | -0.005 | 3.81 | -1.63 | -0.401 |